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Abstract 
Background: The Gag polyprotein is a multifunctional regulator of retroviral replication and major structural compo‑
nent of immature virions. The nucleic acid chaperone (NAC) activity is considered necessary to retroviral Gag func‑
tions, but so far, NAC activity has only been confirmed for HIV‑1 and RSV Gag polyproteins. The nucleocapsid (NC) 
domain of Gag is proposed to be crucial for interactions with nucleic acids and NAC activity. The major function of 
matrix (MA) domain is targeting and binding of Gag to the plasma membrane but MA can also interact with RNA and 
influence NAC activity of Gag. Here, we characterize RNA binding properties and NAC activity of HIV‑2 MA and Gag, 
lacking p6 domain (GagΔp6) and discuss potential contribution of NC and MA domains to HIV‑2 GagΔp6 functions 
and interactions with RNA.
Results: We found that HIV‑2 GagΔp6 is a robust nucleic acid chaperone. HIV‑2 MA protein promotes nucleic acids 
aggregation and tRNALys3 annealing in vitro. The NAC activity of HIV‑2 NC is affected by salt which is in contrast to 
HIV‑2 GagΔp6 and MA. At a physiological NaCl concentration the tRNALys3 annealing activity of HIV‑2 GagΔp6 or MA 
is higher than HIV‑2 NC. The HIV‑2 NC and GagΔp6 show strong binding to the packaging signal (Ψ) of HIV‑2 RNA 
and preference for the purine‑rich sequences, while MA protein binds mainly to G residues without favouring Ψ RNA. 
Moreover, HIV‑2 GagΔp6 and NC promote HIV‑2 RNA dimerization while our data do not support MA domain partici‑
pation in this process in vitro.
Conclusions: We present that contrary to HIV‑1 MA, HIV‑2 MA displays NAC activity and we propose that MA domain 
may enhance the activity of HIV‑2 GagΔp6. The role of the MA domain in the NAC activity of Gag may differ signifi‑
cantly between HIV‑1 and HIV‑2. The HIV‑2 NC and MA interactions with RNA are not equivalent. Even though both 
NC and MA can facilitate tRNALys3 annealing, MA does not participate in RNA dimerization in vitro. Our data on HIV‑2 
indicate that the role of the MA domain in the NAC activity of Gag differs not only between, but also within, retroviral 
genera.
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Background
The retroviral Gag polyprotein is not only a major struc-
tural component of immature virions, but also acts as 
multifunctional regulator of virus replication [1–4]. The 
Gag polyproteins of human immunodeficiency viruses 
type 1 and 2 (HIV-1 and HIV-2) share 50  % sequence 
homology and each contains the N-terminal matrix (MA) 
domain, which is responsible for Gag targeting and bind-
ing to the plasma membrane [5, 6], the capsid domain 
(CA), which facilitates Gag multimerization [4, 7], and 
the nucleocapsid (NC) domain that interacts with viral 
and cellular nucleic acids (NA) [2, 3, 8]. Gag also contains 
two spacer regions (SP1, SP2) and the p6 domain located 
at the C-terminus, which is necessary for virus release 
from the infected cell [9]. Before or shortly after virion 
release, the Gag polyprotein is cleaved in a highly ordered 
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manner by viral protease into freestanding MA, CA, and 
NC proteins [1, 10]. In addition to the structural function 
in mature virions [4], the NC protein plays an important 
role in the facilitation of nucleic acid strand transfers 
during reverse transcription [11]. Mature MA remains 
bound to the viral membrane [4], but it was proposed 
that a fraction of HIV-1 MA also enters newly infected 
cells, associates with the pre-integration complex (PIC), 
and affects proviral DNA circularization and integration 
[12, 13].
At a late stage in the HIV replication cycle, Gag may 
be responsible for the annealing of tRNALys3 to an 18-nt 
primer binding sequence (PBS) localized in the 5′UTR 
of the viral RNA, where tRNALys3 primes reverse tran-
scription [2, 14]. The NAC activity is considered nec-
essary to anneal tRNALys3 but, so far, it has only been 
confirmed for HIV-1 and Rous sarcoma virus (RSV) Gag 
proteins in vitro [15–18]. Chaperone proteins can facili-
tate folding and formation of the most thermodynami-
cally favoured structures of nucleic acids [19]. The NAC 
activity of HIV-1 Gag has been shown to depend on the 
NC domain, which is required for tRNALys3/viral RNA 
complex formation [14, 16, 17], whereas the MA domain 
can inhibit this process via RNA binding [17]. Numer-
ous lines of evidence support the nucleic-acid-binding 
properties of retroviral MA [15, 20–27], but significant 
differences in the role of MA domain in the overall NAC 
activity of Gag were observed between retroviral genera. 
In contrast to HIV-1, the chaperone activity of alpharet-
rovirus RSV Gag is independent of the MA domain [15]. 
Moreover, HIV-1 and RSV NC display robust chaper-
one activity [15–17, 28], whereas MA proteins from 
both viruses do not promote annealing of primer tRNA 
in vitro [15–17]. The RNA-binding properties and chap-
erone activity of HIV-2 Gag have not been studied and 
the contribution of NC and MA domains remains unde-
fined. We recently reported that HIV-2 NC is an effective 
NAC, but its activity is limited by the structural stability 
of the nucleic acid molecule to a much greater degree 
than that of HIV-1 NC [29].
As a nucleic acid chaperone, Gag binds NA non-spe-
cifically [2, 3], but is also engaged in highly specific rec-
ognition of cis-acting dimerization and packaging (Ψ) 
signals within the 5′UTR of the viral genomic RNA [30]. 
Although HIV-1 Gag binds GU-rich sequences in the 
cytoplasm, its binding specificity changes to A-rich RNA 
motifs during virion assembly [31]. The HIV-2 Gag-
binding sites within the viral RNA remain uncharacter-
ized and only limited information on HIV-2 NC binding 
to isolated domains of HIV-2 5′UTR in vitro is available 
[32, 33]. Similar packaging mechanisms are suggested for 
both viruses [34], but HIV-1 Gag is able to package HIV-2 
RNA, whereas HIV-2 Gag cannot package HIV-1 RNA 
[35, 36]. The NC domains of HIV-1 and HIV-2 uncleaved 
Gag polyproteins are proposed to be crucial for the selec-
tion, dimerization, and packaging of viral RNA [8, 36–
39]. In contrast, both NC and MA domains play direct 
roles in viral RNA packaging in deltaretroviruses [bovine 
leukaemia virus (BLV) and human T cell leukaemia virus 
type 2 (HTLV-2)] [22, 25, 26]. Interestingly, participation 
of the MA domain of HIV-1 Gag in these steps of viral 
replication was also suggested [23, 40, 41]. Moreover, an 
intriguing link between a mutation in the MA domain of 
HIV-2 Gag and viral RNA dimerization has been recently 
shown [42].
The three-dimensional structure of the entire HIV-1 
and HIV-2 Gag is unknown, but the structures of their 
freestanding NC and MA have been presented [32, 43–
46]. Moreover, the structure of the non-myristoylated 
HIV-1 Gag fragment (MA-CA-SP1-NC) was recently 
resolved by NMR spectroscopy [27]. The mature NC 
proteins of HIV-1 and HIV-2 are small basic proteins, 
containing two zinc finger domains (ZFs). The ZFs are 
proposed to be crucial for specific interactions of NC 
with nucleic acids, whereas basic residues from the dis-
ordered N-terminus play a role in non-specific interac-
tions and NAC activity [8, 11, 29, 47]. Despite the limited 
sequence similarity between HIV-1 MA and HIV-2 MA, 
both proteins are composed of six α-helices and three 
β-sheet elements, and are myristoylated at the N-termi-
nus [43, 44, 46]. The myristyl group and amino acid resi-
dues of HIV-1 and HIV-2 MA are engaged in PM binding 
[5, 43]. Importantly, some of those residues are located 
within the highly basic region (HBR) at the N-terminus of 
MA, which is proposed to be important for interactions 
with RNA in HIV-1 [21, 48–50]. RNA binding to the MA 
domain ensures the specificity of HIV-1 Gag interactions 
with PM phospholipids [6, 21, 48, 51]. Whether the MA 
domain of HIV-2 Gag is involved in RNA binding is not 
known.
Within this work we characterized the RNA-binding 
properties and nucleic acid chaperone activity of recom-
binant HIV-2 GagΔp6, NC and MA proteins. We iden-
tified binding sites of HIV-2 GagΔp6 and isolated NC 
and MA domains within the 5′UTR of HIV-2 RNA. 
Both HIV-2 NC and GagΔp6 show strong binding to 
the packaging signal and preference for the purine-rich 
sequences, while HIV-2 MA binds mainly to G residues 
without favouring Ψ RNA. Moreover, HIV-2 NC pro-
motes HIV-2 RNA dimerization while this process is not 
supported by HIV-2 MA, suggesting that MA domain 
is dispensable for HIV-2 GagΔp6-promoted dimeriza-
tion in  vitro. We found that HIV-2 GagΔp6 is a robust 
nucleic acid chaperone and we propose that both NC 
and MA domains contribute to nucleic acids aggrega-
tion and tRNALys3 annealing in vitro. The NAC activity of 
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HIV-2 NC is affected by salt in contrast to that of HIV-2 
GagΔp6 and MA.
Results
Nucleic acid‑binding properties of HIV‑2 GagΔp6, MA, 
and NC
Interactions of HIV-1 Gag polyprotein as well as NC 
and MA proteins with nucleic acids are documented 
(reviewed in Ref. [3]). However, little information, and 
limited to freestanding NC [32, 33], is available for HIV-2. 
Therefore, the first step of our study was to characterize 
the binding of non-myristoylated HIV-2 Gag polyprotein 
lacking the p6 domain (referred to as GagΔp6) and free-
standing HIV-2 NC and MA proteins to RNA. We per-
formed salt-dependent filter-binding assays to examine 
interactions with three RNA molecules that represent 
functional domains of 5′UTR of HIV-2 genomic RNA: 
TARpA, PBS, and Ψ (Fig. 1) [33, 52, 53].
At physiological salt concentration (150  mM NaCl), 
the highest binding affinity was observed for Ψ RNA 
and HIV-2 GagΔp6 or NC (15 and 71 nM, respectively) 
(Table 1). However, GagΔp6 binding was salt-independ-
ent up to 250  mM NaCl, while NC affinity to Ψ RNA 
decreased nine-fold within a 100–250  mM NaCl range. 
At physiological salt concentration GagΔp6 displayed 
slightly lower affinity to PBS and TARpA than to Ψ 
RNA. A similar but more apparent trend was observed 
for HIV-2 NC protein, whereas HIV-2 MA bound PBS, 
TARpA and Ψ RNA with comparable affinities. Both 
HIV-2 NC and MA bound non-Ψ RNA molecules with 
similar affinities, but MA binding to Ψ RNA was sig-
nificantly weaker than that of NC. Contrary to HIV-2 
NC, GagΔp6 and MA consistently showed resistance to 
increasing salt within a 100–250  mM range, indepen-
dently of the RNA substrate used. Importantly, even at 
500  mM NaCl, HIV-2 GagΔp6 remained tightly bound 
to Ψ (Kd  ≈  125  nM) and PBS (Kd  ≈  314  nM) RNAs 
and only GagΔp6/TARpA interaction was reduced 
(Kd  ≈  965  nM). Both HIV-2 NC and MA proteins 
showed significantly lower affinity to RNA at 500  mM 
NaCl and only NC/Ψ RNA interaction was somewhat 
tighter.
Hydroxyl radical (HR) footprinting was used to further 
characterize HIV-2 GagΔp6, NC, and MA interactions 
with HIV-2 5′UTR. Overall reactivity profiles for RNA in 
the presence or absence of HIV-2 GagΔp6, NC, or MA 
Fig. 1 Schematic representation of HIV‑2 proteins (a) and RNAs (b) used in this study
Table 1 Calculated dissociation constants for  HIV-2 NC, 
MA, and GagΔp6 complexes with selected RNA
NaCl (mM) Kd (nM)
NC MA GagΔp6
TARpA RNA
 50 207 ± 9 431 ± 88 49 ± 5
 100 285 ± 21 417 ± 74 52 ± 5
 150 385 ± 16 430 ± 46 53 ± 5
 200 541 ± 6 538 ± 68 65 ± 4
 250 679 ± 16 593 ± 76 97 ± 7
 500 1432 ± 22 2377 ± 209 965 ± 83
PBS RNA
 50 36 ± 3 335 ± 28 31 ± 1
 100 117 ± 6 289 ± 4 31 ± 3
 150 196 ± 9 290 ± 5 30 ± 2
 200 277 ± 26 340 ± 25 31 ± 2
 250 392 ± 37 382 ± 25 41 ± 3
 500 2036 ± 212 2072 ± 98 314 ± 29
Ψ RNA
 50 7 ± 2 413 ± 52 27 ± 1
 100 25 ± 1 300 ± 41 17 ± 1
 150 71 ± 1 312 ± 29 15 ± 1
 200 135 ± 4 357 ± 21 24 ± 2
 250 240 ± 10 374 ± 19 26 ± 3
 500 979 ± 26 1514 ± 210 125 ± 5
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were compared to reveal RNA sequences protected when 
proteins were present. At the highest protein concentra-
tion, almost the entire HIV-2 leader RNA was protected 
from HR cleavage for all proteins studied. The strongest 
decreases in HR cleavage were observed in the presence 
of HIV-2 GagΔp6 and NC proteins, while lesser effects 
were observed at the same concentration of HIV-2 MA, 
which supports the RNA-binding analysis (Table  1). A 
strong decrease in susceptibility to HR was noted for all 
studied proteins within TAR, PBS, and domains within 
the 3′ end of the 5′UTR (Fig.  2a). Several sites within 
the PBS domain that were protected from cleavage in 
the presence of HIV-2 GagΔp6 were also protected by 
MA but not NC, while reduced reactivities for some 
sequences within the 3′ end of the 5′UTR that were noted 
in the presence of HIV-2 GagΔp6 were also observed 
in the presence of NC but not MA. HIV-2 GagΔp6 or 
NC protected mostly purine residues, whereas mostly 
G residues displayed reduced cleavage in the presence 
of MA (Additional file  1). The protection patterns were 
detected in both single and double-stranded regions. 
Analysis of the composition of protected sites and their 
vicinity revealed a prevalence of G residues in the case of 
MA, A residues for NC, while mixed nucleotide residue 
composition was observed for HIV-2 GagΔp6 (Fig. 2b).
HIV‑2 MA displays high TAR annealing activity
The capability to facilitate the annealing of HIV-1 TAR 
RNA and TAR(−) DNA hairpins serves as a basic test 
of the in  vitro NAC activity of proteins [54]. This assay 
resembles the annealing of (–) ssDNA to 3′UTR of viral 
RNA during the first strand transfer of reverse tran-
scription. HIV-1 NC and Gag were found to be excel-
lent nucleic acid chaperones, whereas HIV-1 MA 
displays little, if any, NAC activity [16, 17, 25]. We have 
recently shown that HIV-2 NC displays robust annealing 
a b
Fig. 2 Protein binding to HIV‑2 5′UTR. a Secondary structure model of +1–560 nt region of HIV‑2 RNA [33] with the positions protected from 
hydroxyl radical cleavage in the presence of the HIV‑2 GagΔp6, NC, and MA proteins marked. The level of protection increases with protein con‑
centration. Closed circles indicate residues protected starting at lowest protein concentration; open circles indicate residues protected starting at 
intermediate protein concentration. Light grey annotates lack of data. b Sequences within binding sites and their vicinities were compared using 
http://weblogo.berkeley.edu/ [68]
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activity of HIV-1 TAR hairpins [29], but the NAC activ-
ity of HIV-2 MA and Gag has not been reported yet. 
Therefore, the concentration and time course TAR RNA/
TAR(−) DNA gel-shift annealing assays were performed 
to characterize and compare the NAC activity of HIV-2 
MA, NC, and GagΔp6. A comparison of the proportion 
of annealed product obtained at increasing concentra-
tions of HIV-2 MA, NC, or GagΔp6 showed that all ana-
lysed HIV-2 proteins effectively facilitated the annealing 
reaction (Fig. 3a). At 0.2 µM concentration (1 protein per 
3.9 nt) of HIV-2 GagΔp6, NC, or MA, over 75 % of the 
TAR(−) DNA was annealed. However, on a molar basis, 
HIV-2 GagΔp6 is a more effective chaperone than NC 
or MA, since a twofold lower concentration of GagΔp6 
was sufficient for maximal percentage of TAR annealing. 
Moreover, in the presence of 0.05 µM HIV-2 GagΔp6, the 
annealing was ~60 %, whereas no significant amount of 
annealed products was observed at the same concentra-
tion of HIV-2 NC or MA. Similarly to the observations 
made previously for HIV-1 GagΔp6 [16], we found that a 
further increase in HIV-2 GagΔp6 concentration led to a 
decrease in annealed products.
Subsequently, time course TAR annealing at 0.2  µM 
protein concentration (1 protein per 3.9 nt) was per-
formed to compare the annealing rates of HIV-2 NC, 
MA, and GagΔp6 (Fig. 3b). We found that the annealing 
rate of HIV-2 NC is higher than that of GagΔp6 and MA 
(twofold and threefold, respectively) (Table 2). However, 
the final levels of TAR hairpins annealed in the presence 
of each analysed HIV-2 protein were similar and close 
to 95 %. To directly compare HIV-2 and HIV-1 MA pro-
teins, the ability to facilitate TAR annealing was assayed 
for HIV-1 MA (Fig.  3a, b). In agreement with previous 
study [25], low level of TAR annealing (~16 %) was meas-
ured in the presence of HIV-1 MA.
HIV‑2 MA effectively aggregates nucleic acids
The ability to sequence non-specific aggregation of NA is 
considered an important characteristic of NAC proteins 
[55]. We directly compared the NA-aggregation proper-
ties of analysed HIV-2 proteins and HIV-1 MA using sed-
imentation assays (Fig. 3c). In this assay, the 32P-labelled 
HIV-1 TAR(−) DNA and TAR RNA were incubated with 
increasing concentrations of protein, centrifuged, and 
the amount of non-aggregated NA was measured. We 
found that HIV-2 NC, MA, and GagΔp6 are effective 
NA-aggregating agents, since ~80  % of NA aggregation 
was detected at a 0.2 µM concentration of each protein. 
The observed NA aggregation at a given protein concen-
tration was similar for HIV-2 NC and MA, but signifi-
cantly greater for HIV-2 GagΔp6, since a two-fold lower 
Fig. 3 Comparison of HIV‑2 GagΔp6, MA, NC and HIV‑1 MA nucleic 
acid chaperone activity. a TAR annealing assays in the presence of 
increasing concentrations of protein. b Time course TAR annealing 
assays using 0.2 µM of each protein (1 protein per 3.9 nt). The curves 
are single‑exponential fits to average data. Representative gels are 
included in Additional file 2. c TAR(−) DNA aggregation by the differ‑
ent proteins
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concentration of GagΔp6 was sufficient for the maximal 
NA aggregation. HIV-1 MA aggregated NA much weaker 
than HIV-2 proteins since only up to ~40 % of aggrega-
tion was detected at the highest protein concentration 
used (0.8 µM).
NC and MA domains may contribute to the tRNALys3 
annealing activity of HIV‑2 Gag
The HIV-1 Gag and NC, via their NAC activity, medi-
ate tRNALys3 annealing in  vitro and in  vivo [14, 17, 36]. 
On the contrary, HIV-1 MA does not promote the tRN-
ALys3 annealing in vitro even when high MA concentra-
tions and long reaction times were employed [17]. The 
aggregation and TAR annealing assays demonstrated that 
HIV-2 MA displays high NAC activity in vitro (Fig. 3). To 
further characterize and compare the activity of the ana-
lysed HIV-2 proteins, gel-shift tRNALys3 annealing assays 
were performed, using the in vitro transcribed, unmodi-
fied tRNALys3, and a 560-nt RNA, corresponding to the 
5′UTR of HIV-2 genomic RNA (Fig.  1b). To determine 
the influence of salt on the NAC activity of proteins, the 
annealing reactions were conducted at low (20 or 50 mM) 
and physiological (150 mM) NaCl concentrations.
The annealing assays showed that HIV-2 GagΔp6 
displays high tRNALys3 annealing activity and, on a 
molar basis, is an even better chaperone than HIV-2 
NC (Fig.  4a, b). Moreover, in contrast to HIV-2 NC, 
GagΔp6 activity is not influenced by NaCl concentra-
tion. In the presence of 1 µM HIV-2 GagΔp6, the anneal-
ing was ~70  % at 20 and 150  mM NaCl. At the same 
concentration of HIV-2 NC, only 25  % of annealing 
was measured at 20 mM NaCl, whereas no activity was 
observed at 150 mM NaCl. Furthermore, at 1.5 µM con-
centration (1 protein per 3.9 nt) of HIV-2 NC the pres-
ence of 150 mM NaCl reduced the annealing activity by 
80 % and, even at 3 µM NC (1 protein per 1.8 nt), reduc-
tion by 30 % was still observed. Interestingly, in the pres-
ence of 0.5 µM HIV-2 MA, ~25 and ~37 % annealing of 
tRNALys3 was achieved at 20 and 150 mM NaCl, respec-
tively (Fig. 4a, b). These results suggest that an increase in 
salt concentration stimulates to some extent the activity 
of HIV-2 MA. Although HIV-2 MA promoted tRNALys3 
annealing at lower concentrations than HIV-2 NC, in 
contrast to NC, a further increase in its concentration up 
to 3 µM (1 protein per 1.8 nt) did not lead to an increase 
in annealing. In our hands, and in agreement with pre-
vious results [17], HIV-1 MA did not promote tRNALys3 
annealing even at high protein concentration and during 
an extended period of reaction (Fig. 4).
The time course tRNALys3 annealing assays performed 
at 1.5  µM protein concentration (1 protein per 3.9 nt), 
revealed important differences between the anneal-
ing rates of HIV-2 NC, MA, and GagΔp6 at 20 mM and 
150 mM NaCl (Fig. 4c, d). At low NaCl, HIV-2 NC dis-
played a significantly higher (~11-fold) annealing rate 
than HIV-2 GagΔp6 or MA. The observed final percent-
ages of tRNALys3 annealed were similar for HIV-2 NC 
and GagΔp6 (~95 and ~85 %, respectively), and ~38 % in 
the presence of HIV-2 MA. At physiological NaCl con-
centration, the annealing rates and final percentages of 
annealing in the presence of HIV-2 MA and GagΔp6 did 
not change significantly. Interestingly, HIV-2 NC exhib-
ited an almost 27-fold lower annealing rate and the final 
percentage of tRNALys3 annealed was reduced to ~38 %. 
The increase in HIV-2 proteins concentration to 3 µM (1 
protein per 1.8 nt) did not change the observed trend and 
inhibitory effect of 150 mM NaCl was still observed for 
HIV-2 NC but not for HIV-2 MA or GagΔp6 (Table 2).
HIV‑2 MA does not promote HIV‑2 RNA dimerization
HIV-2 genomic RNA is packaged as a dimer into the 
virions and, as in other retroviruses, Gag is involved 
in genome dimerization and packaging [35, 37, 38]. It 
was presented that, similarly to HIV-1, the intact NC 
domain within the uncleaved HIV-2 Gag confers spe-
cific binding of dimerization and Ψ signals via its two 
zinc finger motifs [37]. Our results showed that free-
standing HIV-2 MA binds several sequences of HIV-2 
RNA that are important for dimerization and packag-
ing (Fig. 2a). To elucidate the role of the MA domain in 
HIV-2 RNA dimerization, in vitro assays in the presence 
of HIV-2 GagΔp6, MA, and NC were performed. In con-
trast to HIV-1, HIV-2 RNA forms tight dimers in  vitro 
Table 2 Annealing parameters of HIV-2 NC, MA, GagΔp6
HIV‑2 protein (μM) Annealing rate NA annealed (%)
TAR annealing (20 mM NaCl)
 NC (0.2) 2.0 ± 0.40 95.3 ± 0.7
 MA (0.2) 0.6 ± 0.05 91.1 ± 2.4
 GagΔp6 (0.2) 0.9 ± 0.11 92.5 ± 1.3
tRNALys3 annealing (20 mM NaCl)
 NC (1.5) 1.87 ± 0.44 95.1 ± 1.8
 MA (1.5) 0.17 ± 0.08 37.8 ± 5.0
 GagΔp6 (1.5) 0.18 ± 0.06 85.1 ± 5.2
tRNALys3 annealing (150 mM NaCl)
 NC (1.5) 0.07 ± 0.03 35.8 ± 4.9
 MA (1.5) 0.21 ± 0.06 48.1 ± 4.9
 GagΔp6 (1.5) 0.26 ± 0.03 82.1 ± 3.4
 NC (3) 0.11 ± 0.02 43 ± 5.2
 MA (3) 0.22 ± 0.07 60 ± 4.9
 GagΔp6 (3) 0.37 ± 0.07 90 ± 3.7
RNA dimerization (150 mM NaCl)
 NC (6) 0.48 ± 0.10 49.2 ± 1.6
 GagΔp6 (6) 0.15 ± 0.01 45.7 ± 2.2
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inefficiently, so the +1–444 transcript derived from the 
5′UTR of HIV-2 RNA was chosen, since it forms dimers 
in  vitro more efficiently than the entire (560 nt) 5′UTR 
[56]. The +1–444 transcript contains sequences pro-
posed to be involved in HIV-2 genome dimerization: 
palindrome of SL1, called DIS (dimer initiation site), Ψ 
sequence with palindrome pal, and TAR domain [33, 
38, 42, 56, 57]. We observed that HIV-1 MA and HIV-2 
MA were unable to induce dimerization in vitro, whereas 
both HIV-2 NC and GagΔp6 facilitated the dimeriza-
tion of +1–444 RNA (Fig. 5). In comparison to annealing 
assays, a significantly lower concentration of HIV-2 NC 
or GagΔp6 (1 protein per 30 nt) was needed to obtain the 
maximum percentage of RNA dimer (Fig. 5a). This obser-
vation is consistent with the hypothesis that, at the initial 
steps of packaging, a limited number of Gag is engaged 
in genome selection and dimerization [37]. Surprisingly, 
regardless of the presence of 150  mM NaCl in dimeri-
zation assays, HIV-2 NC was more effective on a molar 
basis than HIV-2 GagΔp6 and exhibited a three-fold 
higher dimerization rate (Fig. 5a; Table 2).
Discussion and conclusions
In this work, we investigated the chaperone activity of 
HIV-2 GagΔp6, MA, and NC proteins, their binding 
specificity, and interactions with HIV-2 RNA. We also 
included HIV-1 MA in chaperone assays for direct com-
parison. The results of NA aggregation, TAR, or tRN-
ALys3 annealing assays showed that, on a molar basis, 
HIV-2 GagΔp6 is a more robust nucleic acid chaperone 
than NC. Moreover, at a physiological salt concentration, 
the rate and final percentage of annealed tRNALys3 were 
significantly higher in the presence of HIV-2 GagΔp6 
than HIV-2 NC (Fig. 4b, c; Table 2). The salt-dependent 
binding assays revealed that HIV-2 GagΔp6 binds to 
RNA with higher affinity than freestanding HIV-2 NC 
(Table 1). These observations suggest that domains other 
than NC contribute to the NAC activity of HIV-2 Gag. 
Fig. 4 Protein induced tRNALys3 annealing in the presence of varying NaCl concentrations. a and b Concentration course annealing assays. c and d 
Time course annealing assays using 1.5 µM of each protein (1 protein per 3.9 nt), the curves are single‑exponential fits to average data. Representa‑
tive gels are included in Additional file 2
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Indeed, we found that HIV-2 MA binds RNA and dis-
plays high NAC activity in vitro, since it effectively aggre-
gated NA and facilitated the annealing of TAR hairpins 
(Fig. 3). This is in contrast to HIV-1 MA, which displays 
very poor NA aggregation and TAR annealing activity 
(Fig.  3) [25]. In addition HIV-1 MA does not chaper-
one tRNALys3 annealing in vitro while in the presence of 
HIV-2 MA, up to ~50 % of tRNALys3 annealing was meas-
ured (Fig.  4). In low salt concentration HIV-2 MA dis-
plays reduced tRNALys3 annealing activity compared to 
that of HIV-2 NC and GagΔp6. However the difference 
in activity is less evident in TAR annealing assays, sug-
gesting that NAC activity of HIV-2 MA is limited by sub-
strates length and stability to a greater degree than that of 
HIV-2 NC or GagΔp6.
We observed that HIV-2 GagΔp6 and MA binding to 
RNA is salt-independent in the range from 50 to 250 mM 
NaCl (Table 1). Consistently with these results, the tRN-
ALys3 annealing activity of HIV-2 GagΔp6 and MA was 
not sensitive to monovalent salt at 20–150  mM (Fig.  4). 
Contrary to our data on HIV-2 MA, the increase in mono-
valent salt concentration from 50 to 150 mM significantly 
decreased the RNA-binding affinity of HIV-1 MA [25]. 
The RNA-binding properties and NAC activity of HIV-2 
NC are highly salt-sensitive. At a physiological NaCl con-
centration, the extent and rate of tRNALys3 annealing in 
the presence of HIV-2 NC were lower than in the pres-
ence of HIV-2 MA (Fig.  4; Table  2). The comparison of 
the HIV-2 NC and MA chaperone activity at different salt 
concentrations supports involvement of both RNA-bind-
ing domains of HIV-2 GagΔp6 in tRNALys3 annealing.
Based on the presented results, we propose that both 
NC and MA domains contribute to the chaperone activ-
ity of HIV-2 Gag. Although HIV-2 NC is an effective 
chaperone, its activity is lower than that of HIV-1 NC 
[29]. Additionally to the NC domain, the MA domain via 
interactions with RNA and its NAC activity may enhance 
the activity of HIV-2 Gag. However we cannot exclude 
influence of other domains or multimerization on the 
NAC activity of HIV-2 Gag. The available data indicate 
that for HIV-1 the NC domain is primarily responsi-
ble for the overall NAC activity of HIV-1 Gag [16, 17], 
whereas the MA domain via RNA binding inhibits the 
NAC activity of HIV-1 Gag [17]. Interestingly, the MA 
domain does not influence the NAC activity of RSV Gag 
(alpharetrovirus) [15], while the HTLV-2 MA protein 
(deltaretrovirus) displays significantly higher chaperone 
activity than HTLV-2 NC [25]. Our data on HIV-2 indi-
cate that the role of the MA domain in the NAC activity 
of Gag may differ not only between, but also within, ret-
roviral genera.
The residues important for the chaperone activity of 
deltaretroviral MA proteins are highly conserved, includ-
ing the presence of positively charged amino acid resi-
dues, and are located in α-helix II [25]. In case of HIV-1 
MA two basic residues within the corresponding region 
(α-helix II) are also conserved between the HIV-1 and 
related SIV subtypes (Fig.  6a) but are not sufficient to 
confer NA chaperone activity. However, substitution 
of E40R/E42L/N47K in HIV-1 α-helix II resulting in 
the basic character mimicking HTLV-2 MA increased 
HIV-1 MA NAC activity to the level comparable to that 
of HTLV-2 [25]. In case of HIV-2 and related SIV sub-
types this region is less positively charged than that of 
HIV-1 MA (Fig.  6a). Interestingly, calculated [58] iso-
electric point is higher for the full length MA protein of 
HIV-2 than HIV-1 MA (9.68 and 9.10, respectively). The 
Fig. 5 Protein‑induced dimerization of HIV‑2 RNA. a +1–444 RNA 
dimerization in the presence of increasing concentrations of proteins. 
b Time course dimerization in the presence of 6 µM protein (1 protein 
per 30 nt). The curves in panel b are single‑exponential fits to average 
data. Representative gels are included in Additional file 2
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observed differences in the NAC activity of MA proteins 
may result from the more basic character of HIV-2 MA 
relative to HIV-1 MA. This is further supported by the 
analysis of electrostatic potential surfaces of HIV-1 and 
HIV-2 MA (Additional files 3 and 4). The amino acid res-
idues of HBR were shown to be responsible for the RNA 
binding in HIV-1 MA [48]. The sequence alignment of 
HIV-1, HIV-2 and related SIV isolates demonstrated high 
level of conservation of the HBR between those retrovi-
ruses (Fig.  6b). Since HIV-1 MA do not promote tRN-
ALys3 annealing it is unlikely that HBR region is a major 
determinant of HIV-2 MA chaperone activity. Analysis of 
the electrostatic potential surfaces of HIV-2 and HIV-1 
MA proteins reveals regions other than α-helix II or HBR 
that might be considered important for HIV-2 MA NAC 
activity (Additional files 3 and 4). The difference between 
electrostatic potential surfaces of the two proteins was 
observed e.g. in the C terminus. The C terminus of MA 
proteins is disordered [43, 46]. Unstructured regions con-
taining basic residues able to nonspecifically interact with 
nucleic acids are suggested to be important for the pro-
teins’ NAC activity [19, 29, 47, 59]. On the other hand, 
relatively high salt resistance (up to 250  mM) of HIV-2 
MA (Table 1) may suggest that some specific interactions 
contribute to HIV-2 MA/RNA binding.
A recent study has shown that HIV-1 Gag exhibits sig-
nificant differences in salt-dependent binding to diverse 
HIV-1 RNA fragments and binds non-Ψ RNA with low 
specificity via its NC and MA domains, whereas bind-
ing to Ψ RNA is highly specific and only the NC domain 
is engaged [60]. Such a binding model is not common 
to all retroviral Gag polyproteins, since, in deltaretro-
viruses (HTLV-2), the MA domain binds RNA more 
specifically than NC and plays a dominant role in the 
initial recognition of the Ψ signal in genomic RNA [25]. 
Our results demonstrate that HIV-2 GagΔp6 binds both 
Ψ and non-Ψ RNAs with high specificity, which was 
manifested by a negligible change in the dissociation 
constants within the 50–250 mM NaCl range (Table 1). 
Moreover, even at 500 mM NaCl, HIV-2 GagΔp6 inter-
acted with Ψ RNA and non-Ψ (PBS) RNA with strong 
affinities (Kd  ≈  125 and 314  nM, respectively). HIV-2 
GagΔp6 binding to Ψ RNA was similar to that pre-
sented for HIV-1 GagΔp6, but HIV-1 GagΔp6 did not 
bind non-Ψ RNA (TARpA) at 500 mM NaCl [60]. HIV-2 
GagΔp6 bound TARpA at 500 mM NaCl but with affin-
ity (Kd ≈ 965 nM) lower than PBS. At low ionic strength 
(50 mM NaCl), HIV-2 NC binding to Ψ RNA was com-
parable to that of HIV-2 GagΔp6, but highly susceptible 
to salt concentration. HIV-2 NC and MA bound non-Ψ 
RNA with comparable affinity, but MA binding to Ψ 
RNA was notably weaker than that of NC or GagΔp6. 
Taken together, our results suggest contributions of both 
the NC and MA domains to the interactions of HIV-2 
Gag with RNA, but the NC domain plays a major role in 
recognizing the Ψ signal. Our results showing that HIV-2 
GagΔp6 and NC, but not MA, occupy some of the sites 
within the Ψ region of 5′UTR may further support this 
notion. Although the majority of HIV-2 GagΔp6, NC, and 
MA binding sites cluster within the Ψ region of HIV-2 
5′UTR, extensive interactions were also detected within 
the TAR and PBS domains (Fig. 2). A recent study dem-
onstrated that the RNA-binding specificity of HIV-1 Gag 
changes during viral replication [31]. Only a few regions 
of the viral RNA interacted with HIV-1 Gag in cytosol, 
including the 5′UTR, while the entire RNA was covered 
within the virus particles. Interestingly, the binding of 
HIV-1 Gag to TAR observed in the cytosol was HIV-1 
subtype-dependent. Several lines of evidence suggested 
that TAR might be important for HIV dimerization and 
packaging [61, 62]. Moreover, TAR stability is considered 
important in the strand transfer during reverse transcrip-
tion [63] and may also influence the Gag translation effi-
ciency [64]. Our in  vitro conditions are likely in favour 
of the detection of the high-affinity binding sites, but 
without differentiation of the replication stage. Binding 
of HIV-2 GagΔp6, NC, and MA to PBS in the vicinity of 
the tRNALys3 binding regions may support their involve-
ment in primer annealing. Indeed, all proteins promoted 
Fig. 6 Sequence alignment of a MA α‑helix II and b highly basic 
region (HBR); from HIV and related SIV subtypes. Sequences were 
taken from HIV Sequence Database (http://hiv.lanl.gov) and at least 
hundred sequences were align for each group. Alignments were 
visualized using http://weblogo.berkeley.edu/ [68]
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tRNALys3 annealing to the 5′UTR (Fig.  4). Interestingly, 
findings that HIV-1 Gag has a strong preference for 
G-rich binding sites in cells and A-rich in virions [31] is 
reflected in our in vitro binding studies, showing a high 
purine content within the HIV-2 GagΔp6 binding sites.
In HIV-2 RNA, packaging and dimerization signals 
overlap, and the NC domain of HIV-2 Gag is proposed 
to be required for viral genome dimerization and packag-
ing in vivo [37, 38, 56]. Indeed, we found that HIV-2 NC 
and GagΔp6 effectively promote in vitro dimerization of 
HIV-2 RNA containing DIS and pal dimerization signals 
(Fig. 5). For HIV-1 Gag, numerous lines of evidence sup-
port the involvement of the NC domain in the genomic 
RNA selection, dimerization, and packaging, but several 
observations suggest a contribution of the MA domain 
to these processes [41]. It was found that the presence of 
either the NC or the MA domain is required for genome 
packaging during HIV-1 particle assembly [23, 40]. 
However, a recent study revealed that the MA domain 
of HIV-1 Gag binds almost exclusively to specific cellu-
lar tRNAs [31]. Our data suggest that the MA domain 
is dispensable for HIV-2 GagΔp6-promoted dimeriza-
tion, since this process is not supported by HIV-2 MA 
in vitro. On the other hand, HIV-2 MA binds some cis-
acting dimerization and packaging sequences in 5′UTR 
of HIV-2 RNA (Fig. 2). Therefore, we cannot exclude the 
participation of the MA domain in HIV-2 genome selec-
tion and dimerization in the cell.
Methods
Cloning, expression and purification of recombinant 
proteins
The HIV-2ROD NC protein was obtained using pGEX-
4T-3-NCp8 as described previously [33]. Sequences 
encoding HIV-2 MA, GagΔp6 (HIV-2ROD isolate) and 
HIV-1 MA (HIV-1NL4-3 isolate) were PCR amplified 
from HIV-2 pROD10-EVA232 and pNL4-3-ARP2006 
(National Institute for Biological Standards and Con-
trol, Centre for AIDS Reagents, UK). PCR products were 
digested, purified using PureLink® spin columns (Invit-
rogen), and cloned into a pGEX-4T-3 expression vector. 
The sequence of each construct was confirmed by DNA 
sequencing. The glutathione S-transferase (GST) fusion 
HIV-2 NC, MA, and GagΔp6 and HIV-1 MA recombi-
nant proteins were expressed in One Shot® BL21(DE3)
pLysS E. coli (Invitrogen) and purified by affinity chro-
matography on Glutathione Sepharose (GE Healthcare) 
as described in the Additional file  5. The GST tag was 
removed by thrombin cleavage. The purity of proteins 
was assessed by SDS–PAGE and estimated to be above 
90  %. Protein concentrations were determined by their 
absorption spectrum and protein samples were aliquoted 
and stored at −80 °C.
DNA and RNA substrates
TAR(−) DNA, corresponding to the trans activation 
response (TAR) sequences of HIV-1MAL, was 32P-labelled 
at the 5′-end with [γ-32P]ATP using T4 polynucleotide 
kinase (Fermentas) and purified using NucAway Spin 
Columns (Life Technologies). HIV-1 TAR RNA and 
unmodified human tRNALys3 (referred to here as tRN-
ALys3) were obtained using a PCR-generated template 
(Additional file  6) and Ambion T7-MEGAshortscript. 
Transcripts were purified by denaturing gel electrophore-
sis (8 M urea) in 1 × TBE, followed by elution and etha-
nol precipitation. The tRNALys3 was 3′-end labelled using 
[α-32P]pCp and T4 RNA ligase (Fermentas) and purified 
on G50 columns (GE Healthcare). Templates for in vitro 
transcription of HIV-2 RNA molecules were obtained 
by PCR amplification of fragments from the HIV-2 
plasmid pROD10-EVA232 using a forward primer con-
taining a  T7 promoter sequence (Additional file  6). The 
RNA molecules were as follows: TARpA (nt +1–188), 
PBS (nt +197–379), Ψ (nt +380–560), RNA +1–444, 
5′UTR (nt +1–560) and RNA +1–891. RNAs were syn-
thesized using T7-MEGAscript (Ambion) and purified 
using Direct-zol™ RNA MiniPrep (Zymo Research). The 
integrity of the RNAs was assessed by agarose gel elec-
trophoresis under denaturing conditions. Purified RNA 
was stored at −20 °C. For some assays, RNA was 3′-end 
labelled using [α-32P]pCp and T4 RNA ligase (Fermentas) 
following purification using Direct-zol™ RNA MiniPrep 
(Zymo Research).
Filter‑binding assay
Equilibrium-binding experiments were performed as 
described previously [59] with the following modifi-
cations. Reactions were carried out in binding buffer 
(20  mM HEPES–KOH pH 7.5, 1  mM MgCl2, 10  µM 
TCEP, 5  mM β-mercaptoethanol, 10  µM ZnCl2, and 
50–500 mM NaCl). The final concentration of RNA was 
0.2 nM. The binding reactions were incubated for 25 min 
at room temperature and then 50 µl of each reaction was 
filtered and washed with 200 µl of binding buffer contain-
ing 50  mM NaCl. After filtration, the membranes were 
dried and exposed to a phosphoimager screen. Data were 
analysed using Multigauge (Fuji) and Origin (OriginLab) 
software.
Hydroxyl radical footprinting and detection of RNA 
cleavage products
RNA +1–891 was used for footprinting experiments 
(Additional file  6) and the secondary structure of the 
5′UTR within this RNA was confirmed previously [33]. 
RNA samples (5  pmol) were heated at 95  °C for 1  min 
and slowly cooled to 4  °C. Subsequently, buffer was 
added to the final concentration of 40 mM Tris–HCl, pH 
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8.0, 130 mM KCl, 0.5 mM EDTA, and 5 mM MgCl2, and 
samples were incubated for 25 min at 37 °C. Folded RNA 
samples were diluted 20-fold with 20  mM Tris–HCl, 
pH 8.0, followed by addition of NC, MA, or GagΔp6 
(6 μl of 3 µM, 6 µM, or 12 µM protein in the buffer con-
taining 50  mM Tris–HCl, pH 8.0, 1  M NaCl, 6.7  mM 
β-mercaptoethanol, 2.5  mM DTT, 0.1  mM ZnCl2) to a 
70  μl reaction. RNA/protein complexes were formed 
at 0  °C for 20  min. Footprinting reactions were initi-
ated by applying on the wall of the tube 1 μl of 2.5 mM 
(NH4)Fe(SO4)2, 50  mM sodium ascorbate, 1.5  % H2O2, 
and 2.75  mM EDTA, and centrifugating. After 15  s at 
24 °C, reactions were quenched by the addition of 20 μl 
of stop solution containing 0.1  M thiourea and 0.2  M 
EDTA. RNA were purified using Direct-zol RNA Mini-
Prep Kit (Zymo Research). For the reverse transcrip-
tion reactions, a total of 1.5 pmols of RNA was mixed 
with 2  µl of fluorescently labelled primer 186, 540, or 
787 (Additional file  6) [4  μM Cy5 (with reagent) and 6 
uM Cy5.5 (without reagent)] and 12  μl of primer-tem-
plate solutions were incubated at 85 °C for 3 min, 60 °C 
for 5 min, 35 °C for 5 min, and 50 °C for 2 min. Reverse 
transcription and sample processing were carried out 
as previously described [65]. Sequencing ladders were 
prepared using a Thermo Sequenase Cycle Sequenc-
ing Kit (Affymetrix) according to the manufacturer’s 
protocol. Samples and sequencing ladders were puri-
fied using a ZR DNA Sequencing Clean-up Kit (Zymo 
Research) and analysed on a GenomeLab GeXP Analy-
sis System (Beckman-Coulter). Three to nine repetitions 
were obtained for each read. Electropherogram peaks 
were converted to reactivity values using Shapefinder 
software [66]. Reverse transcription stops in the control 
reaction were identified as outlying high peaks in the 
plotted background area. To normalize the data, peak 
intensity for each nucleotide was divided by the average 
intensity of the 8 % most reactive peaks excluding outli-
ers. The outliers were defined as greater than 1.5 times 
the interquartile difference above the 3rd quartile [67]. 
Normalized data were averaged and nucleotide posi-
tions corresponding to reverse transcription stops were 
excluded from further analysis. Differences between 
reactivity values for reaction without protein and con-
taining protein were calculated. The consistent drop in 
reactivity with increasing protein concentration larger 
than at least 20  % of reactivity value was regarded as a 
possible binding site.
To estimate number of binding sites within differ-
ent domains of 5′UTR for HIV-2 GagΔp6, NC and MA, 
number of residues protected from hydroxyl radical 
cleavage in the presence of only GagΔp6 and NC were 
compared to the number of those protected only in the 
presence of GagΔp6 and MA.
TAR annealing assay
32P-labelled HIV-1 TAR(−) DNA (1 nM) and unlabelled 
HIV-1 TAR RNA (6  nM) were heat denaturated and 
folded separately in buffer containing 20 mM Tris–HCl, 
pH 7.5, 30 mM NaCl, 0.1 mM MgCl2, 10 µM ZnCl2, and 
5 mM DTT. Then, the mixture of both oligonucleotides 
was incubated with increasing concentrations of each 
protein (0–0.8 µM) at 37  °C for 5 min. The time course 
assays were conducted at 37  °C using 0.2  µM protein 
and the samples were removed at the indicated time 
points. All reactions were quenched with 0.5 volume of 
stop solution (20 % glycerol, 20 mM EDTA pH 8.0, 0.1 % 
SDS, 0.25  % bromophenol blue, and 0.4  mg/ml yeast 
tRNA). Samples were analysed by native PAGE (8 %) in 
0.5 × TBE at 4 °C.
Sedimentation assays
32P-labelled HIV-1 TAR(−) DNA (1  nM) was com-
bined with complementary unlabelled TAR RNA in a 
buffer containing 50 mM Tris pH 7.5, 20 mM NaCl, and 
0.2  mM MgCl2. Reactions (10  µl) were incubated with 
increasing protein concentrations (0–0.8  µM) at 37  °C 
for 5 min. Subsequently, the mixtures were centrifuged at 
11,400 rpm for 20 min. Supernatants (2 µl) were collected 
and subjected to scintillation counting.
tRNALys3 annealing assay
32P-labelled tRNALys3 (2  nM) and unlabelled +1–560 
HIV-2 RNA (10 nM) were refolded in 50 mM Tris–HCl, 
pH 7.5 by heating at 95 °C for 1 min and slow cooling to 
37 °C, followed by addition of MgCl2 to 10 mM and place-
ment on ice. The annealing buffer contained 50 mM Tris–
HCl pH 7.5, 5 mM DTT, and 1 mM MgCl2, and different 
NaCl concentrations of 20, 50, or 150 mM. The mixture 
was incubated at 37  °C for 10 min, followed by addition 
of protein and further incubation for 10  min. The time 
course assays were conducted at 37 °C using 1.5 or 3 µM 
protein and the aliquots were removed at the indicated 
time points. All reactions were quenched by incubation 
with 1 % (w/v) SDS at room temperature for 5 min. The 
samples were phenol/chloroform-extracted, mixed with 
loading buffer (50 % glycerol with dyes), and separated on 
1.4 % SDS-agarose gel in 1 × TBE at room temperature.
RNA dimerization
The unlabelled +1–444 HIV-2 (400  nM) spiked with 
the trace amount of the same 32P-labelled transcript was 
heat denatured in 50 mM Tris–HCl pH 7.5, 40 mM KCl, 
150 mM NaCl, and 0.1 mM MgCl2. The mixture was slowly 
cooled to 37 °C and placed on ice, followed by addition of 
different concentrations of proteins. The dimerization was 
allowed to proceed at 37  °C for 30  min. The time course 
dimerization assays were conducted at 37  °C using 6  µM 
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protein and the aliquots were removed at the indicated 
time points. All dimerization reactions were quenched by 
incubation with 1  % (w/v) SDS at room temperature for 
5 min, phenol/chloroform-extracted, and mixed with load-
ing buffer (50 % glycerol with dyes). The products were sep-
arated on 1 % agarose gel in 1 × TBE at room temperature.
All gels were autoradiographed and quantitatively ana-
lysed by phosphorimaging using a FLA-5100 phospho-
rimager with MultiGaugeV 3.0 software (FujiFilm). The 
obtained data were analysed using Origin (OriginLab) 
software. All graphs represent averaged data from three 
or more independent experiments with standard devia-
tions indicated. In all cases, at least three independent 
experiments were performed, and the data presented are 
representative of the whole.
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